

Research Article
Open Access

Examination of Sexual Hormone Levels of the Hypothalamus- Pituitary - Gonad Axis and the Influence of Methadone Dose in the Treatment of Chinese Heroin Addicts

 Haoran Zhang¹ and Zhimin Liu^{2*}
¹College of Preschool Education, Beijing Youth Politics College, Beijing 100102, PR China

²National Institute on Drug Dependence, Peking University, 38 Xueyuan Road Haidian District, Beijing 100191, China

ABSTRACT

Background: Sexual function decline in male heroin addicts during methadone maintenance treatment (MMT) is a problem, and the link between methadone doses and sex hormone levels in this group is unclear. This cross-sectional study explored HPG axis hormone levels and their association with methadone doses in Chinese MMT-treated heroin addicts.

Methods: All participants provided blood samples. Sexual hormones, including testosterone (T), progesterone (P), prolactin (PRL), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2), were measured using radioimmunoassay (RIA). The relationship between different methadone doses (" ≤ 30 mg/d", "31 - 60mg/d", and " ≥ 61 mg/d") and sex hormones was analyzed via general linear modeling (GLM).

Results: The study included 103 male heroin addicts receiving methadone maintenance treatment (MMT) and 79 healthy male controls. No significant differences were found in the levels of all sex hormones among different methadone doses (all $P > 0.05$). After adjusting for age and the duration of MMT, no significant associations were detected between different methadone doses and the six hormone levels.

Conclusion: No dose-response relationship was observed for the six hormone levels. The significance of considering the independence of methadone dose effects on the HPG axis hormone levels of heroin addicts in MMT should be carefully evaluated.

***Corresponding author**

Zhimin Liu, Professor, National Institute on Drug Dependence, Peking University, 38 Xueyuan Road Haidian District, Beijing, 100191, China.

Received: February 20, 2025; **Accepted:** February 24, 2025; **Published:** March 05, 2025

Keywords: Methadone Dose, Hypothalamus-pituitary-gonad axis Male, Heroin Addicts, China

Introduction

Since the initiation of a methadone maintenance treatment (MMT) pilot program in China in February 2003, it has achieved remarkable outcomes in preventing HIV/AIDS and reducing drug-related harms in recent years. However, several issues remain in practical implementation. For example, how to address the sexual function decline in male heroin addicts is a pressing concern. Previous studies have indicated that the prevalence of sexual dysfunction is higher in the methadone-maintained population compared to the general population [1-3]. Sexual dysfunction is a common complaint among drug abusers, and its resolution is crucial for MMT patients to adhere to treatment and lead a normal life. The stability of the hypothalamus-pituitary-gonad (HPG) axis is essential for normal physiological function, and the sex hormones secreted by the HPG axis play a vital role in maintaining and regulating body functions [4-8]. The restoration of sexual function in heroin addicts after detoxification is significant for reducing relapse rates and facilitating their reintegration into society. Nevertheless, some studies suggest that opiate drugs may directly suppress the pituitary gland and testicles. Given

the lack of knowledge regarding the sex hormone levels of male heroin addicts during MMT, the first objective of this study was to measure the concentrations of testosterone, progesterone, estradiol, luteinizing hormone, follicle-stimulating hormone, and prolactin in both heroin addicts and healthy men.

Multiple factors have been proposed to influence the response to methadone maintenance treatment (MMT) [9]. Among these, the dosage is considered a critical factor [10-13]. However, determining an appropriate and optimal methadone dose remains a significant challenge [14]. Crowley reported that high methadone doses could significantly decrease the frequencies of male sexual behaviors [15]. Kreek's research showed that the hormone levels of the hypothalamus-pituitary-gonad (HPG) axis would return to normal as libido normalized [16]. Thus, we hypothesized that the underlying cause of sexual dysfunction in heroin addicts might be related to changes in sex hormones. Since the impact of methadone doses on sex hormones and the potential association between them were unknown, the second objective of this study was to explore the relationship between methadone doses and HPG axis hormones in male heroin addicts undergoing MMT. Considering the scarcity of relevant studies in China, we conducted a two-group, cross-sectional study. This research is expected to assist

MMT practitioners and professionals in initiating treatment with appropriate methadone doses and, more importantly, promoting the recovery of MMT patients.

Methods

Samples

The survey was conducted from November 2024 to January 2025. A consecutive sample of 103 male heroin addicts receiving stable-dose methadone maintenance treatment (MMT) in Xi'an City, Shaanxi Province, was recruited. The inclusion criteria were as follows:

- Meeting the DSM - IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; American Psychiatric Association, 1994b) criteria for opiate dependence;
- Being male and 18 years old or older
- Currently receiving MMT for more than 1 month
- Willing to sign an informed consent agreement
- Being able to comply with the study protocol
- Not taking medications such as antidepressants or corticosteroids.

The exclusion criteria were:

- Inability to identify the primary drug of abuse;
- Having severe psychotic disorders
- Suffering from severe physical diseases (e.g., liver or kidney diseases, prostate problems)
- Having language or comprehensive cognitive deficits.

For the control group, the inclusion criteria were:

- Being healthy male individuals
- Aged 18 years or above
- Having no history of drug abuse and showing no evidence of drug abuse during the study
- Being able to provide written informed consent

The main reasons for refusal to participate were:

- Having severe psychiatric diseases (e.g., obsessive - compulsive disorder, amnesia, or schizophrenia)
- Suffering from severe physical diseases (e.g., liver or kidney diseases, prostate problems)
- Having recent or remote memory impairments. Ultimately, 79 cases were eligible for the control group.

Data Collection and Measures

This study was a cross-sectional survey. Prior to the formal investigation, a pilot study was conducted. The researchers involved in the survey were trained by experienced experts in specific survey techniques. Each participant was briefly informed about the research objectives to obtain their support and cooperation, after which written informed consent was obtained from all participants. A questionnaire with detailed baseline variables was provided by the National Institute on Drug Dependence, Peking University. Current socio-demographic characteristics and substance use histories were collected through face - to - face interviews. All completed questionnaires were reviewed by researchers for completeness and consistency. Incomplete or inconsistent questionnaires were excluded from the final analysis. Subjects in the MMT were not randomly assigned to a specific dose level; the decision to increase or decrease the maintenance dosage was made by the attending doctor. Each participant was assigned a study serial number, which they were asked to record in the signature file. Blood specimens were collected before breakfast. Five milliliters of venous blood was drawn into non - gel - top tubes and allowed to clot spontaneously at room temperature for 30 minutes. After centrifugation at 4000 rpm for 8 minutes,

serum was collected. The samples were then divided into two 1-ml tubes and immediately frozen at below - 20°C. All assays were performed in one batch upon the completion of the study. Sexual hormones, including testosterone (T), progesterone (P), prolactin (PRL), follicle - stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2), were measured using radioimmunoassay (RIA). The intra - assay coefficients of variation for the hormone measurements using the reagent kits were all less than 10.0%, and the inter - assay coefficients of variation were all less than 15.0%.

Statistical Analysis

During the study's observation period, the methadone doses of the participants ranged from 6 mg to 110 mg per day, with a mean dose of $(47.7 \pm 23.40 \text{ mg/d})$ and a median dose of 40.0 mg/d. Nearly half of the participants (49.0%) took a dosage between 31-60mg/d, approximately 30% took a dosage of $\leq 30\text{mg/d}$, and 21.6% took a dosage higher than 60 mg daily. Based on the actual methadone administration levels in China and Blaney's study, the methadone-maintained patients were classified into three groups according to their daily dose levels: a low - dose group ($\leq 30 \text{ mg/d}$), a medium - dose group (31-60mg/d), and a high - dose group ($\geq 61\text{mg/d}$) [17]. The healthy controls were designated as the no - dose group. Statistical analysis was performed using SPSS software for Microsoft Windows. Quantitative variables with a symmetric distribution were described by the mean and standard deviation, while those with a skewed distribution were described by the median. Non-parametric statistical tests were employed when the distribution was non-normal. Descriptive statistics were used to analyze the distributions of demographic characteristics and hormone levels. One-way analysis of variance (ANOVA) or the Chi - Square test was used to explore differences among the three methadone-dose groups. The Kruskal-Wallis H test was applied to investigate potential differences in each HPG axis hormone level across groups. Additionally, general linear modeling (GLM) was utilized to examine the association between HPG axis sex hormone levels and different methadone doses ($\leq 30 \text{ mg/d}$, 31-60 mg/d, and $\geq 61 \text{ mg/d}$). Potential confounding factors in this study included the subjects' age and the duration of MMT. Notably, significant differences in the duration of MMT were observed among different dose groups. Therefore, age and the duration of MMT were adjusted for in the actual analysis. All statistical significance tests were two - tailed, with an alpha level of 0.05.

Ethics Consideration

Before the interviews and blood sampling, participants were informed about the study's purpose, and their consent to participate was obtained. The survey procedures were designed to protect participants' privacy through anonymity. Participants had the right to withdraw from the study at any time. The study was approved by the Ethical Committee of Peking University Health Center (Grant No. IRB00001052 - 10026).

Results

Baseline Data of Study Participants from Three Methadone-Dose Groups

The age of the 103 MMT individuals ranged from 20 to 52 years, with a mean age of 39.5 ± 6.8 years. The participants in this study had diverse educational backgrounds and marital statuses. Most (66.0%) had a junior high school education or lower, and only 1.0% had a university - level education. Among the total samples, over half (60.8%) were married. The mean age of the 79 healthy men was 32.8 years (standard deviation, $SD = 9.8$), with an age range of 19 to 55 years. Overall, there were no significant differences in dose among the three groups ($P > 0.05$). The subjects' age,

education, marital status, and duration of methadone maintenance treatment (MMT) across different methadone - dose groups are presented in Table 1. The distributions of age, educational level, and marital status did not differ significantly among the different methadone doses. However, the duration of MMT differed significantly among the three dose groups ($P < 0.001$).

Trends in Hormone Levels of the HPG Axis by Three Different Methadone Doses

As shown in Table 2, no significant differences were detected in the hormone levels of the hypothalamus - pituitary - gonad (HPG) axis among different methadone doses (all $P > 0.05$). When compared with the healthy controls, significant differences were found in all six hormones in the " ≤ 30 mg/d" group ($P < 0.05$); in the "31 - 60 mg/d" group, significant differences were observed in five hormones except testosterone (T) ($P < 0.05$); and in the " ≥ 61 mg/d" group, only the levels of T and progesterone (P) differed significantly from those of the healthy controls ($P < 0.05$). When comparing each sex hormone, the T levels in the low - and high - methadone - dose groups were higher than those in the healthy controls ($P < 0.05$); the P levels in all three dose groups were lower than those in the controls ($P < 0.05$); the prolactin (PRL) and luteinizing hormone (LH) levels in the low - and medium - methadone - dose groups were higher than those in the controls ($P < 0.05$), while the follicle - stimulating hormone (FSH) and estradiol (E2) levels in the low - and medium - methadone - dose groups were lower than those in the controls ($P < 0.05$). The Kruskal - Wallis H test indicated no significant differences in sex hormones among the three methadone - dose groups ($P > 0.05$). However, after adjusting for age and the duration of MMT, the trends in sex hormone levels with different methadone doses became notable (see Figure 1). In particular, the levels of T, P, FSH, and LH exhibited a biphasic change pattern in individuals treated with different methadone doses. Conversely, PRL levels decreased and E2 levels increased with increasing methadone doses.

Relationship Between Methadone Doses and Hormone Levels of the HPG Axis

To account for confounding factors, general linear modeling (GLM) was used to examine the association between different methadone doses (≤ 30 mg/d, 31 - 60 mg/d, and ≥ 61 mg/d) and sex hormone levels, with age and the duration of MMT as adjusted variables. Table 3 shows that the interaction between variables and intercepts did not differ significantly among the three dose groups ($P > 0.05$), indicating that further association analysis was feasible. As presented in Table 4, GLM analysis revealed that the association between the three methadone doses and all sex hormone levels did not reach statistical significance ($P > 0.05$).

Discussion

This study demonstrated that the sexual hormone levels of heroin addicts receiving methadone treatment differed from those of healthy men, and there were also differences in sex hormone levels among the three methadone-dose groups. Moreover, different methadone treatment doses were not associated with sex hormone secretion.

In the present study, no association was found between sex hormone levels and methadone doses in male heroin addicts undergoing methadone maintenance treatment (MMT). For instance, testosterone (T) levels were not correlated with different methadone doses ($F = 1.230$, $P = 0.299$), which is consistent with some previous studies [18,19]. Additionally, this study did not detect an association between different methadone doses and

luteinizing hormone (LH) ($F = 0.755$, $P = 0.473$) or follicle - stimulating hormone (FSH) ($F = 0.287$, $P = 0.752$). Furthermore, the results did not support the hypothesis that methadone dose had a significant effect on progesterone (P) ($F = 0.249$, $P = 0.780$), prolactin (PRL) ($F = 0.620$, $P = 0.541$), and estradiol (E2) ($F = 0.310$, $P = 0.735$). Overall, there were no significant differences between methadone doses and sex hormone levels, suggesting that the appropriate dose for an individual may be more crucial than the categorization of low, medium, or high doses [20]. Rose found that a daily methadone dose of 130 mg caused severe erectile dysfunction (ED), while an individual's sexual function recovered after switching to a 40 - mg daily dose, and the serum LH and FSH concentrations returned to normal [21]. In our study, only 21.6% of the subjects took a dosage higher than 60 mg daily, which was considered a high methadone dose. Thus, for the Chinese drug-using population in this survey, tolerance to the opiate - induced suppression of pituitary gonad hormones may have developed. However, our findings should be interpreted with caution because in drug-using populations, HPG axis dysfunction is influenced by multiple factors, including the direct effects of drugs and the indirect effects of other factors [22-25].

This study found that the testosterone (T) level in methadone - maintained cases was higher than that in healthy controls, which contradicts some previous studies showing reduced T levels in opiate addicts and in men using methadone [26-32]. Several possible explanations exist for these differences. Firstly, the rehabilitation of pituitary function depends on the regulation of the central nervous system (CNS) and hypothalamus (LH). In our study, the function of the CNS and the regulation of LH disrupted by opiates may have gradually recovered under methadone treatment. Secondly, the increased secretion of LH may be a contributing factor to the elevated T levels. It is known that serum T can regulate the synthesis and secretion of serum LH through a feedback mechanism, and elevated LH stimulates Leydig cells, leading to an increase in serum T concentrations [33]. Thirdly, opiate drugs can inhibit PRL secretion, which has a negative feedback effect on LH release [34]. Therefore, we concluded that the inhibited PRL may affect the negative feedback of T release.

In this investigation, no significant differences were found between sex hormone levels and methadone doses, and over half (57.8%) of the participants had been in methadone maintenance treatment (MMT) for more than 12 months. Thus, it can be tentatively concluded that long-term methadone-maintenance treatment may not have a restorative effect on the HPG axis. The inhibition of the HPG axis may be mainly attributed to the long - term history of heroin addiction.

These findings should be interpreted in the context of the following limitations. First, this study was unable to obtain the blood specimens of the samples prior to their enrollment in methadone maintenance treatment (MMT). Consequently, we were unable to establish the baseline hormone levels and lacked the means to closely monitor the dynamic changes in hormone levels during MMT. Second, in the present survey, only healthy men were selected as the control group. To expand the scope of our observations, it is necessary to examine the hormone levels of male heroin addicts who are not undergoing methadone therapy. Third, the use of convenience sampling limited the representative of the sample. Given that drug abuse is a highly sensitive issue, randomly sampling a hidden population with sensitive parameters is challenging. Our sample was composed of middle - aged individuals (mean age = 39.5 ± 6.8) with relatively low

educational attainment, as 66.4% had less than a junior high school education. Fourth, the hypothalamus - pituitary - gonad (HPG) axis is highly sensitive to various internal and external factors. Stress, depression, gender, seasonal variations, and medications are among the many factors that can influence the HPG axis and its sensitivity. In this study, the investigation was conducted in a stable environment, and only male addicts were surveyed. Individuals with depression and a history of taking medications such as antidepressants or corticosteroids were excluded. However, the potential interactions of hormone levels with other illicit drugs, poly - drug use, alcohol, and seasonal factors were not statistically evaluated. These aspects should be explored in future studies and considered in clinical applications.

In conclusion, this study offer a basic understanding of the relationship between methadone treatment dosages and sex hormones. Given the variations in sex hormone levels across different methadone doses, additional research is essential before making any medical recommendations.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Authors Contributions

ZM Liu conceived and planned the study. HR. Zhang carried out the statistical analyses, drafted the manuscript. All authors read and approved the final manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgments

We acknowledged the extensive support from all staff members at methadone maintenance treatment (MMT) clinic.

Data availability

Data will be made available on request.

References

1. Cun Du, Zhimin Liu (2009) Methadone maintenance treatment in China and related issues. *Chin J Drug Abuse Prevent Treat* 15: 326-330.
2. Ching-Ming Cheng, Yen-Chin Lin, Kun-Chia Chang (2017) Psychological Distress is Correlated with Erectile Dysfunction Among Patients Receiving Methadone Maintenance in Taiwan 13: 312-316.
3. Maximilian Meyer, Patrick Brunner, Leonie Geissmann, Martin Gürtler, Fabienne Schwager, et al. (2022) Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice-Identifying Group Differences and Predictors 22: 846834.
4. Khajehei M (2024) Endorphins, Sexuality, and Reproduction. *Adv Neurobiol* 35: 397-433.
5. Raftogianni A, Roth LC, García-González D, Bus T, Kühne C, et al. (2018) Deciphering the Contributions of CRH Receptors in the Brain and Pituitary to Stress-Induced Inhibition of the Reproductive Axis. *Front Mol Neurosci* 30: 305.
6. Schifano N, Chiappini S, Mosca A, Miuli A, Santovito MC, et al. (2022) Recreational Drug Misuse and Its Potential Contribution to Male Fertility Levels' Decline: A Narrative Review. *Brain Sci* 19: 1582.
7. Nazmara Z, Ebrahimi B, Makhdoumi P, Noori L, Mahdavi SA, et al. (2021) Effects of illicit drugs on structural and functional impairment of testis, endocrinal disorders, and molecular alterations of the semen. *Iran J Basic Med Sci* 24: 856-867.
8. Lehman MN, He W, Coolen LM, Levine JE, Goodmans RL (2019) Does the KNDy Model for the Control of Gonadotropin-Releasing Hormone Pulses Apply to Monkeys and Humans? *Semin Reprod Med* 37: 71-83.
9. Donny EC, Bigelow GE, Stitzer ML, Walsh SL (2005) Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioiddependent volunteers. *Addiction* 100: 1496-1509.
10. Zhao JK, Kral AH, Wenger LD, Bluthenthal RN (2020) Characteristics Associated with Nonmedical Methadone Use among People Who Inject Drugs in California. *Subst Use Misuse* 55: 377-386.
11. Wang L, Min JE, Krebs E, Evans E, Huang D, et al. (2017) Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. *Int J Drug Policy* 49: 32-40.
12. Greenwald MK, Wiest KL, Haight BR, Laffont CM, Zhao Y (2023) Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder. *Harm Reduct J* 2: 173.
13. Gerra G, Manfredini M, Somaini L, Maremmi I, Leonardi C, et al. (2016) Sexual Dysfunction in Men Receiving Methadone Maintenance Treatment: Clinical History and Psychobiological Correlates. *Eur Addict Res* 22: 163-75.
14. Li W, Wang Z, Liu Z (2016) Factors associated with illicit opioid use in methadone maintenance treatment clients in 5 Provinces, China. *Environ Health Prev Med* 21: 480-486.
15. Zhang M, Zhang H, Shi CX, McGoogan JM, Zhang B, et al. (2014) Sexual dysfunction improved in heroin-dependent men after methadone maintenance treatment in Tianjin, China. *Plos One* 10: e88289.
16. Kreek MJ (1992) Epilogue: Medical Maintenance Treatment for Heroin Addiction, from a Retrospective and Prospective Viewpoint. *State Methadone Maintenance Treatment Guidelines Office for Treatment Improvement, Division for State Assistance* November 255-272.
17. Blaney T (1999) Methadone Maintenance Does Dose Determine Differences in Outcome? *J Subst Abuse Treat* 16: 221-228.
18. Bestepe EE, Tunali N, Sarıdoğan GE (2020) Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/ Naloxone Combination Treatment for Opioid Use Disorders. *Neuropsychiatr Dis Treat* 12: 2695-2705.
19. Keleş DB, Bilici R, Ayık B, Kılıç MK, Kliewer W (2024) Comparing attention, impulsivity, and executive functions between patients with opiate use disorder: Buprenorphine maintenance treatment versus active users, in comparison with healthy controls. *Indian J Psychiatry* 66: 90-97.
20. Cao X, Wu Z, Rou K, Li L, Lin C, et al. (2014) Retention and its predictors among methadone maintenance treatment clients in China: a six-year cohort study. *Drug Alcohol Depend* 1: 87-93.
21. Rose RE (1996) Hypogonadism and methadone: Hypogonadism after long-term use of high-dose methadone [J]. *Endocr Pract* 2: 4-7.
22. Henry A, Longcope (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men:

-
- longitudinal results from the Massachusetts Male Aging Study. *Journal of Clinical Endocrinology and Metabolism* 87: 589-598.
23. Adelson M, Bodner G, Kreek MJ (2007) Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients. *J Addict Dis* 26: 15-26.
 24. Rettori V, Fernandez-Solari J (2010) Alcohol and endocannabinoids: Neuroendocrine interactions in the reproductive axis. *Exp Neurol* 224: 15-22.
 25. Brown R, Mundt M (2005) Methadone maintenance and male sexual dysfunction [J]. *J Addict Dis* 24: 91-106.
 26. Brown R, Balousek S, Mundt M, Fleming M (2005) Methadone maintenance and male sexual dysfunction. *J. Addict. Dis* 24: 91-106.
 27. Brown R, Kraus C, Fleming M, Reddy S (2004) Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. *Postgrad. Med J* 80: 654-659.
 28. Roberts L, Pullan P (2002) Sex hormone suppression by intrathecal opioids: A prospective study. *Clin J Pain* 18: 144-148.
 29. Bliessener N, Schwager A (2005) Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. *Clin Endocrinol Metab* 90: 203-206.
 30. Abs R, Maeyaert J (2000) Endocrine consequences of long-term intrathecal administration of opioids. *Clin Endocrinol Metab* 85: 2215-2222.
 31. HWD (2002) Narcotic-induced hypogonadism during therapy for heroin addiction. *Addict Dis* 21: 47-53.
 32. Finch PM, Price L (2000) Hypogonadism in patients treated with intrathecal morphine. *Clin J Pain* 16: 251-254.
 33. Battista N, Rapino C, Di Tommaso M, Bari M, Pasquariello N, Maccarrone M (2008) Regulation of male fertility by the endocannabinoid system. *Mol Cell Endocrinol* 286: 17-23.
 34. Grattan DR (2008) Prolactin: a pleiotropic neuroendocrine hormone. *J Neuroendocrinol* 20: 752-763.

Copyright: ©2025 Zhimin Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.